Overview

Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL

Status:
Recruiting

Trial end date:
2025-09-01

Target enrollment:

Participant gender:

Summary

CLL2-BZAG is a prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by obinutuzumab (GA101), zanubrutinib (BGB-3111) and venetoclax (ABT-199) in patients with relapsed/refractory CLL.

Phase:

Phase 2

Details

Lead Sponsor:

German CLL Study Group

Treatments:

Bendamustine Hydrochloride
Obinutuzumab
Venetoclax
Zanubrutinib